Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Apogee Therapeutics, Inc. - Common Stock (NQ: APGE ) 45.30 +1.07 (+2.42%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Apogee Therapeutics, Inc. - Common Stock < Previous 1 2 Next > IPO watch 2024: Which new stocks will hit the market? January 08, 2024 Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies. Via MarketBeat Topics Initial Public Offering Exposures Securities Market Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results November 13, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session December 22, 2023 Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. Via Benzinga Apogee Therapeutics to Participate in Upcoming November Investor Conferences October 30, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire 7 Biotech Stocks to Get In Now Before Investors Catch On October 23, 2023 Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. Via InvestorPlace Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress September 27, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day September 14, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results August 28, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board August 21, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 August 08, 2023 Via Benzinga Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases August 07, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics to Participate in Upcoming August Investor Conferences August 02, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares July 18, 2023 From Apogee Therapeutics, LLC Via GlobeNewswire Apogee, Sagimet Debut This Week In First Big IPOs Of Summer July 16, 2023 Sagimet and Apogee both made their trading debuts this week, raising cash for their clinical trials after upsizing their respective IPOs. Inflammation and immunology biotech Apogee had the larger of... Via Talk Markets < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.